arrow
E

Emerson C. Perin

chi st. luke’s health
H指数:45
被引数:8,963

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy

CATO研究的设计与原理:一项IIA期、随机、双盲、安慰剂对照研究,评估脐带来源间充质基质细胞单次或多次静脉输注在缺血性心肌病中的疗效。

2025-12-130
OAAI
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial
2022-09-0117
OA
Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data
2022-06-045
OAAI
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial

自体间充质基质细胞和c-kit阳性心脏细胞单独或联合用于缺血性心力衰竭患者的II期研究: CCTRN CONCERT-HF试验

2021-04-13103
OAAI
Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies
2021-03-0211
OA
A Phase II Randomized, Double-blind, Controlled Trial of Combined Mesenchymal Stromal Cells and C-kit plus Cardiac Progenitor Cells in Ischemic Heart Failure: The CCTRN CONCERT-HF Trial
2020-11-171
PRE
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients The CCTRN SENECA Trial

CCTRN SENECA试验在蒽环类药物诱导的心肌病心力衰竭患者中的同种异体间充质细胞治疗

2020-11-0133
OAAI